Long acting GLP-1 receptor agonist (injectable)
Albiglutide 50 mg injection every 4 weeks
ALBI_SC_50MG_Q4W
Related
- All doses pooled: Albiglutide injection
- Albiglutide 100 mg injection every 4 weeks
- Albiglutide 4 mg injection once weekly
- Albiglutide 15 mg injection once weekly
- Albiglutide 30 mg subcutaneous once weekly
- Albiglutide 15 mg injection every 2 weeks
- Albiglutide 30 mg injection every 2 weeks
- Albiglutide 50 mg injection every 2 weeks
- Albiglutide flexible dose injection once weekly
- Albiglutide 50 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.76 (1.00 to 7.07) | 0.15 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.89 (1.31 to 6.20) | 0.47 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.37 (1.06 to 9.84) | 0.43 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.35 (0.46 to 3.43) | 0.57 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.13 (0.08 to 7.87) | 0.58 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.96 (0.05 to 13.40) | 0.45 |